STRAMSEN BIOTECH, INC
Mark DiSiena - MBA, CPA &JD
Chief Financial Officer (CFO)
Mr. Mark DiSiena, a financial powerhouse with an impressive educational background, has joined Stramsen Biotech Inc as its CFO. His credentials speak volumes: Mr. DiSiena holds a Bachelor of Science in Accounting, magna cum laude, with a minor in Political Science from New York University Stern School of Business. He also possesses a Juris Doctor in Securities and Taxation from Vanderbilt University School of Law, and a Master of Business Administration in Strategy from Stanford University Graduate School of Business. This exceptional blend of education uniquely positions Mr. DiSiena to drive Stramsen Biotech's financial success.
Mark Disiena, CPA, Esq., is a licensed Certified Public Accountant in the state of California and a registered, practicing attorney in the state of New York. His dual expertise in accounting and law provides Stramsen Biotech Inc. with valuable insights into financial compliance and legal matters pertinent to the biopharmaceutical industry.
Mark's extensive experience in management, accounting, finance, and auditing spans from his early career at PricewaterhouseCoopers to senior-level roles with multiple private and publicly traded companies. His track record of excellence is evident in his recent positions:
As Vice President, FP&A at Cetera Financial Group based in Los Angeles, California.
In this role, Mr. DiSiena managed a team of seven, providing critical financial data across the organization. He supported the CFO in the company's $1.7 billion acquisition by GenStar and led the implementation of advanced financial reporting systems.
As Chief Financial Officer at AgEagle Aerial Systems (NYSE:UAVS), Mark demonstrated his ability to navigate complex financial landscapes. He led PCAOB audits, streamlined processes, and boosted cash flow efficiency. Notably, he raised $5 million through strategic debt, equity, and conversions, while ensuring compliance with NYSE and SEC regulations. His leadership extended internationally, managing financial personnel in Switzerland and upgrading legacy systems to enhance operational efficiency.
In his role as Interim Chief Financial Officer and Chief Operating Officer at Cresset Advisors, Mark showcased his versatility across various industries. He expertly handled SEC filings for SPACs, RTOs, and IPOs, implemented cutting-edge ERP systems, and spearheaded fundraising efforts. His clients ranged from SaaS companies to space tourism ventures, demonstrating his adaptability and broad expertise.
At Titanium Healthcare, Mark's strategic vision propelled the company from $2 million to $25 million in revenue, achieving positive EBITDA. He successfully raised equity funds from PE firms and individual investors, while implementing comprehensive employee benefit plans that positioned the company as a top-tier employer. His leadership in the PCAOB audit process further solidified the company's financial standing.
Mark's tenure at Decentral Life (NASDAQ:WDLF) showcases his ability to navigate the complexities of taking a company public. He secured $5 million in pre-revenue funding, uplisted the stock from OTC Pink to OTCQB, and positioned the company for potential NASDAQ or NYSE listing. His strategic financial management and regulatory compliance expertise were instrumental in the company's growth.
Throughout his career, Mark has consistently demonstrated his ability to drive financial success, implement cutting-edge systems, and position companies for growth. His unique blend of financial acumen, strategic vision, and leadership skills make him an invaluable asset to Stramsen Biotech Inc. As CFO, Mark is poised to lead our financial strategies, optimize our operations, and drive our company towards unprecedented growth and success in the biopharmaceutical industry.